Water-Soluble Ruthenium(III)-Dimethyl Sulfoxide Complexes:
Chemical Behaviour and Pharmaceutical Properties by Mestroni, G. et al.
WATER-SOLUBLE RUTHENIUM(III)-DIMETHYL SULFOXlDE COMPLEXES:
CHEMICAL BEHAVIOUR AND PHARMACEUTICAL PROPERTIES
G. Mestroni, E. Alessio 1, G, Sava2, S. Pacor2, M. Coluccia3 and A. Boccarelli3
Department of Chemical Sciences, and 2 Institute of Pharmacology, School of Pharmacy,
University of Trieste, 1-34127 Trieste, Italy
3 Department of Biomedical Sciences and Human Oncology, University of Bari, 1-70124 Bari, Italy
Abstract
In this paper we report a review of the results obtained in the last few years by our
group in the development of ruthenium(Ill) complexes characterized by the presence of
sulfoxide ligands and endowed with antitumor properties. In particular, we will focus on
ruthenates of general formula Na[trans-RuC14(R1R2SO)(L)], where R1R2SO =
dimethylsulfoxide (DMSO) or tetramethylenesulfoxide (TMSO) and L nitrogen donor
ligand. The chemical behavior of these complexes has been studied by means of
spectroscopic techniques both in slightly acidic distilled water and in phosphate buffered
solution at physiological pH. The influence of biological reductants on the chemical
behavior is also described. The antitumor properties have been investigated on a number
of experimental tumors. Out of the effects observed, notheworthy appears the capability
of the tested ruthenates to control the metastatic dissemination of solid metastasizing
tumors. The analysis of the antimetastatic action, made in particular on the MCa
mammary carcinoma of CBA mouse, has demonstrated a therapeutic value for these
complexes which are able to significantly prolong the survival time of the treated
animals. The antimetastatie effect is not attributable to a specific cytotoxicity for
metastatic tumor cells although in vitro experiments on pBR322 double stranded DNA
has shown that the test ruthenates bind to the macromolecule, causing breaks
corresponding to almost all bases, except than thymine, and are able to cause interstrand
bonds, depending on the nature of the complex being tested, some of which results active
as cisplatin itself.
Introduction
Despite the leading role played by cis-dichlorodiammineplatinum(II) (hereafter called
cisplatin) and by other platinum complexes in anticancer chemotherapy, the number of
neoplasms that can be succesfully treated with these compounds is still limited. Platinum
derivatives are in fact scarcely active against several malignancies with high social
incidence, such as non-small cell lung carcinomas, lung adenocarcinomas and
adenocarcinomas of the colon and rectum [1-4]. As a consequence, there is a
considerable interest in investigating compounds of other transition metals as potential
antineoplastic agents [5-8]. The aim of this reasearch is that of finding new active
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derivatives with a spectrum of action different from that of cisplatin and, if possible, with
a minor host toxicity. Many different classes of coordination compounds and
organornetallic derivatives have been screened on model tumors with this aim, and some
promising results have been obtained with derivatives of different metals, e.g. Ga [9,10],
Sn [11-13], Rh [14], Au [15], Ti [16-19] and Ru. In this paper we will focus on
ruthenium derivatives.
The antiturnor properties of simple chloro-arnmino-ruthenium(III) derivatives were first
investigated by M.J. Clarke [20-25]. Two complexes of this class, namely cis-
[Ru(NH3)4C12]C1 and/hc-Ru(NH3)3C13 (Figure 1), showed a significant activity against
P388 leukemia, reaching T/C values of 154 and 189, respectively. In more recent years
Keppler and coworkers reported that anionic Ru(III) complexes with eterocyclic nitrogen
ligands (L) of general formula (LH)2[RuC15L] [26] and (LH)[trans-RuC14L2] [27] have
good antitumor activity against several screening tumor lines [28-31]. In particular, two
monoanionic complexes, IrnH[trans-RuC14(Irn)2] (ICR) (Irn = Imidazole) (Figure 1) and
the analogous indazole (Ind) derivative, were shown to possess good activity against the
platinum resistant chemically-induced colorectal tumors in rats.
Figure 1. Some antitumor active ruthenium(Ill)complexes: a)/hc-RuC13(NH3)3; b) cis-
[RuC12(NH3)4]C1; c) (ImH)[trans-RuC14(lm)2] (ICR).
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In this tumor model, whose sensitivity to chemotherapeutic agents is virtually the same
as that of its human counterpart, the ruthenium derivatives resulted considerably more
active in reducing the tumor mass than the clinically used drug, 5-fluorouracil. No
hypothesis was advanced on the mechanism of action of such complexes, which are now
in advanced preclinical stage [31]. An "activation by reduction" mechanism was instead
proposed [20-25] to explain the activity of the chloro-ammino ruthenium derivatives that
are considerably inert toward ligand loss opening up coordination positions. According to
this hypothesis the inert, and therefore inactive, Ru(lll) complexes are considered as
prodrugs that can be activated by an in situ reduction to the corresponding more labile
Ru(II) species. These should be able to form covalent bonds with biological targets after
relatively rapid dissociation of some ligands. A biologically accessible redox potential is
obviously required for a complex in order to fit in such mechanism. A higher
Ru(ll)/Ru(IIl) ratio might be expected in solid tumor tissues, that are generally
considered as reducing, hypoxie environments compared to surrounding, more aerated
tissues [32,33]. This feature would promote accumulation of ruthenium in tumor masses.
Under such hypothesis the selective cytotoxicity of a complex would depend, beside on
other properties such as net charge and liposolubility, on the Ru(llI)/Ru(II) redox
potential and on the rate of electron transfer. It should be noted, however, that even
though Ru(lII) species are usually more inert than the corresponding Ru(ll) derivatives,
the rate of ligand dissociation strongly depends on the nature of the ligands themselves.
For example, the presence of trans-labilizing ligands can considerably enhance the
dissooation rates. Ru(IH) complexes with such features might directly interact with the
biological targets.
The in 4vo distribution of ruthenium, due to its similarities with iron, might be further
affected by interactions with the Fe-transport protein, transferrin [24,25,31,35]. Ru(llI)
has indeed a high affinity for the transferrin Fe-binding sites, and the protein might play
an important role in the cellular uptake mechanism of ruthenium [31,34,35]. In such
hypothesis, an accumulation of ruthenium in tumor masses might be expected, owing to
the high iron requirement of rapidly growing tumor tissues that involves a large number
of transferrin receptors.
Our group has been investigating the biological properties of ruthenium-sulfoxide
complexes since the late seventies. Dimethylsulfoxide (DMSO), like the other sulfoxides
of general formula R1R2SO, is an ambidentate ligand (Figure 2), as it can coordinate to a
metal center either through the sulfur atom (DMAO) or through the oxygen atom
(DMSO) [36,37].
Figure 2. The two main binding modes of dimethyl sulfoxide.
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The binding mode depends both on electronic and steric factors. When S-bonded,
DMSO acts also as a 7r-aeeeptor of electron density and exerts a considerable trans-
labilizing effect. As a 7r-acceptor, DMSO stabilizes metal ions in low oxidation states;
accordingly, the reduction potential of a DMSO complex may be tuned by the number
and binding mode (S- or O-bonding) of coordinated sulfoxides. Finally,
dimethylsulfoxide is known to diffuse very easily through biological membranes and
might improve the diffusion of coordinated metal ions as well.
The work of our group began with the investigation of Ru(II)-DMSO complexes, in
particular cis-and trans-RuC12(DMSO)4 [38-48], and more recently focused on Ru(IlI)
derivatives [49-56]. In this paper we will report a survey of our latest results of
ruthenium(llI)-sulfoxide complexes from three different, but strictly related, points of
view: structure and chemical behavior, antitumor activity and interactions with DNA,
considered as one of the possible molecular targets.
Results and Discussion
Chemical Aspects. The precursors of the compounds subject of this study are
(DMSO)2H[trans-RuC14(DMSO)2] (1) and its sodium salt and mer-RuC13(DMSO)3 (2).
Figure 3. Schematic synthetic pathways to 1 and 2.
CI------
CI----
RuCl. nil20
DMSO
NC
CI (Me2SQ2H+ DMSO
1)
NaCI
MemO
CI
CiMeO
1
Na
OSMe2
CI
CIM’e,O
2)
44G. Mestroni, E. Alessio, G. Sava, S. Pacor, M. Coluccia and A. Boccarelli Metal BasedDrugs
The synthetic pathways to 1 and 2 and their structural features [51] are schematically
reported in Figure 3. A completely analogous scheme might be drawn for the
corresponding tetramethylenesulfoxide (TMSO) derivatives 3 and 4 [49].
The ruthenium(llI)-sulfoxide complexes 1-4, being structurally very similar to the
Ru(III) compounds with heterocyclic nitrogen donor ligands reported by Keppler [26,27],
aptared particularly attractive in the perspective of finding new derivatives to be tested
for antitumor activity. In fact, the anionic compounds are isostructural and isoelectronic
to ICR, with S-bonded sulfoxides replacing the nitrogen ligands. Unlike ICR, however,
the ruthenium-sulfoxide complexes proved to be rather labile in aqueous solution, in
particular at physiological pH where they are readily hydrolized [51 ].
Although complexes 1-4 resulted scarcely attractive for pharmacological development
due to their lability, the investigation of their reactivity led us to observe that one of the
two trans S-bonded sulfoxides could be easily substituted by a nitrogen ligand [55].
According to this reactivity, they become the precursors of two new classes of
ruthenium(III) compounds of general formula Na[trans-RuC14(R2SO)(L)] (A) and
mer,cis-RuC13(R250)(R2SO)(L) (B), (R2SO DMSO, TMSO), with L nitrogen
donor ligand (Scheme 1-2).
Scheme 1
Na[trans-RuC14(R250)2] + L---> Na[trans-RuC14(R2SO)(L)] + R2SO
Scheme 2
mer-RuC13(R2SO)3 + L---> mer,cis-RuC13(R2SO)(R2SO)(L) + R2SO
In the case of the anionic derivatives, sodium could be rather easily replaced by other
cations such as NEt4+ and LH+ (Scheme 3):
Scheme 3
Na[trans-RuC14(R2SO)(L)] + X+ ___> X[trans-RuC14(R2SO)(L)l + Na+
The reaction procedure turned out to be very versatile and, besides the derivative with L
NH3, we prepared derivatives with 5-membered heterocyclic ligands such as imidazole
(lm), N-methylimidazole (Melm), pyrazole (Pz), oxazole (Ox), with 6-membered
heterocyclic ligands such as pyridine (Py) and, finally, with condensed heterocylcic tings
such as indazole (lnd), isoquinoline (Iq) and 1,5,6-trimethylbenzimidazole (Me3Bzm).
The complexes have been fully characterized by common spectroscopic techniques (UV-
vis, IR, NMR) and the crystal structure of some of them was determined [55]. As
expected, replacement of one DM50 with an N-donor ligand involved a strengthening of
the remaining Ru-DMoq9 bond, attributable to the diminished competition for 7r-back
bonding electrons between the two trans ligands. The crystal structure of the imidazole
derivative, Na[trans-RuC14(DMBO)(Im)l (5), is particularly significant to this regard, as
the complex can be considered as a sort of hybrid between the two symmetrically
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disubstituted derivatives 1 and ICR (Figure 4). In complex 5 a remarkable shortening of
the Ru-S bond length with respect to 1 [2.296(1) vs 2.348(1) A] is observed, while the
Ru-N distance is practically the same as in ICR.
Figure 4. Structural comparison of Na[trans-RuC14(DMSO)(Im)] (from ref. 55) with
(DMSO)2H[trans-RuC14(DMSO)2] (from ref. 51) and (Im)H[trans-RuC14(Im)2] (ICR)
(from ref. 27)
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The sodium salts of the anionic derivatives are highly water soluble but the
reproducibility of their formulation is sometime affected by their tendency to crystallize
including DMSO and acetone molecules of crystallization in variable ratio. Perfectly
reproducible elemental analyses are instead obtained with the LH+ and NEt4+
derivatives, which do not have molecules of crystallization and whose solubility is still
high enough for pharmacological tests. The solubility of the neutral complexes is less
pronounced, approximately 2 mg/ml for mer-RuC13(DMSO)2(NH3) and mer-
RuC13(DMSO)2(Im). As expected, the liposolubility of the complexes, measured as
partition coefficient between water and n-octanol, increases on replacing DMSO with
TMSO and on increasing the lipophylicity of the nitrogen ligand (Table 1) [56]. The use
of properly substituted ligands might strongly influence this parameter. A higher
liposolubility is usually associated with an increased capability of crossing cell
membranes through a passive transport mechanism [57].
The redox potential of selected compounds was measured by cyclic voltammetric
experiments [55,56] (Table 1). All complexes undergo a reversible uncomplicated
reduction, with an observed El/2 that falls in the range -0.001 to +0.117 V (vs SSCE).
Neutral derivatives are significantly more reducible than the corresponding anionic
species. No apparent changes in the redox potential result from the substitution of a
DMSO for a TMSO ligand.
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Table 1. Redox potentials, partition coefficients and visible absorption bands of some
Ru(lll) complexes.
Complex
(Im)H[trans-RuC14(Im)2lc
Na[trans-RuC14(DM50)(H20)]
Na[trans-RuC14(DMSO)(NH3)]
Na[trns-RuC14(DMO)(Im)]
Na[trans-RuC14(DM50)(Pz)]
Na[trans-RuC14(DMO)(Ind) ]
Na[trns-RuC14(DM)(1)1
Ev (V vs SSCE)a
-0.511
0.107
0.029
-0.001
0.065
0.089
0.065
3.46
3.79
2.63
3.21
kmx(nm) (v (Maem-X))
464 (592) 395 (5212)
449 (449) 385 (3684)
451 ’i4’3i’ 390 (3644)
456 (673) 389 (4776)
461 (64,) 395 (4357)
45.8 (43.8) 394 (3568)
Na[trans-RuC14(DMSO)(Iq)]
Na[trans-RuC14(TMSO)(Im)]
Na[trans-RuC14(TMSO)(Py)]
Na[trans-RuC14(TMSO)(Iq)]
RuC13(DMSO)2(H20)
RuC13(DMSO)2(NH3)
RuC13(DMSO)2(Im)
0.066
0.062
2.30
3.21
2.80
1.91
458 (488) 395 (3850)
451 (496) 388 (3411)
457 (47.4) 394 (3539)
457 (492) 39 (3497)
0.186 ..426 (1060) 364 (32.60)
0.117 1.00 414 (1174) 355 .(3222)
0.101 0.82 413 (1034) 358 (2529)
a El/2 obtained at Pt electrode: SSCE saturated calomel electrode. ’b p, partition coefficient
=(concentration in watery(concentration in n-octanol), c El/2 obtained at Hg electrode; the signal is
reversible only in the presence of excess imidazole (Ilml/[ICR] 120).
According to the measured El/2, a biological reduction process is thermodynamically
possible for all the derivatives [24]. In this respect it is interesting to compare the El/2
value of 5 with that of ICR, which we found to be -0.511 V under the same conditions.
This last value sits at the lower limit of the biologically accessible potentials suggesting
that, in the hypothesis of an "activation by reduction" mechanism operating in dvo for
these Ru(llI) complexes, the sulfoxide derivatives might be expected to behave quite
differently from ICR despite their structural similarity.
Due to their greater solubility in water, anionic complexes of class A are more attractive
for being developed as drugs. Accordingly, most of the pharmacological and chemical
investigations to date have been focused on this class of compounds. The chemical
behavior of the anionic complexes has been studied both in unbuffered distilled water and
in phosphate-buffered solutions at physiological pH. The stability of the complexes in the
slightly acidic distilled water can give valuable informations concerning the
administration of the product, while the behavior under physiological conditions is strictly
related to the mechanism of action of the complexes and their in 4vo distribution.
a) Distilled water. The evolution with time of the complexes has been followed by
visible spectroscopy and 1H NMR. All complexes behave similarly and are quite inert in
distilled water at 25C, as clearly shown by the rather slow spectral changes with time.
Each complex of class A is characterized by a strong charge-transfer absorption band
around 390 nm (Table 1) whose intensity slowly decreases with time upon dissolution in
water (12hr < tl/2< 24hr, depending on the nature of the nitrogen ligand). No new
spectral feature appears and the process is accompanied by an increase of diffused
background absorption and a decrease of pH, attributed to the formation of poly-oxo or
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poly-hydroxo species [58] as for complexes 1-4. The NMR spectra deserve some
comments, being particularly helpful in determining the chemical behavior of the
complexes in solution. Owing to the paramagnetism of the Ru(IlI) nucleus, 1H NMR
spectra give rather broad peaks dispersed over a wide range of chemical shift. The D20
1H NMR spectra of the anionic complexes A share the common feature of a broad signal
of S-bonded DMSO centered at about -15 ppm [55]. Analysis of the neutral complexes B
was limited to the ammonia and imidazole derivatives, due to solubility limits. Similarly
to the precursor [51], they both have a broad resonance around -14.5 ppm (S-bonded
DMSO) and a slightly sharper signal of equal intensity around 10.7 ppm (O-bonded
DMSO). Owing to their lower intensity, detection of the resonances of the nitrogen
ligand was sometimes difficult, in particular with the slightly soluble neutral derivatives.
Accordingly, due also to the almost total absence of previous reports on this subject, a
complete assignement of the NMR spectra was not attempted. As a general remark, the
NMR spectra of complexes A and B clearly showed that neither DMSO or the nitrogen
ligand are readily replaced in aqueous solution. In the anionic derivatives DMSO slowly
dissociates with time, as shown by the increase of the signal of the free ligand at 2.71
ppm. The amount of DMSO dissociation is between 25 and 50% after 24hr, depending
on the nature of the nitrogen ligand. Dissociation of this latter is remarkably slower. The
inertness of the complexes can be further increased by working at lower pH, such as in
pH 4 acetate buffer, or in the presence of small amounts of DMSO.
b) Physiological pH. Due to the "activation by reduction" hypothesis proposed for
Ru(III) species [20-25], we devoted a particular attention to the effect of biological
reductants on the chemical behavior of the complexes. We found that, at 25C in pH 7.4
phosphate buffer, the anionic complexes are very rapidly reduced by stoichiometric
amounts of monoelectronic biological reductants, such as ascorbic acid, glutathion and
cystein. The reduction can be followed spectroscopically in the visible, since in the
process the solution becomes almost colorless. On the contrary, the reduction with
bielectronic reductants, such as glucose or lactic acid, even though thermodynamically
very favourable, does not occurr. It is worth noting that, under the same experimental
conditions, ICR is unaffected by the presence of either type of reductant. Since the
reduction is much faster than any substitution process, an outer sphere reduction
mechanism can be hypothized. In agreement with the cyclic voltammetry experiments,
the dianionic complex reported in Scheme 4 is very likely the first species formed upon
reduction.
Scheme 4. Behavior of [trans-RuC14(DM,50)(L)]- complexes in the presence of
stoichiometric amounts of monoelectronic reductants.
Cl
Cl CI + 6 > Cl > Cl
v. fast
Ru CI
fast
Ru OH 2
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According to the reactivity of anionic ruthenium(II)-chloride-DMSO complexes [59], a
rather fast chloride dissociation from this species can be reasonably envisaged. Further
chloride dissociation and/or reaction with the reducing agent can not be excluded.
In pure buffered solutions we observed that, upon increasing the pH, the anionic
complexes become increasingly more labile. Three, quite well separated, consecutive
steps can be distinguished at pH 7.4 (25
oC) and separately followed by visible and NMR
spectroscopy. The visible spectral changes occurring during the first step, which lasts
approximately 1 hour at 25C, are represented in Figure 5. The absorption pattern of the
starting complex decreases with an autocatalytic kinetic profile and the spectrum of the
species that builds up, with a maximum around 346 nm, is very similar to those of the
neutral derivatives B. A neat isosbestic point, showing the presence of only two species
in solution, is maintained during the process. According to this pattern, dissociation of a
chloride was the most likely process occurring in step 1. This hypothesis was confirmed
by NMR data since, during step 1, the original signals of S-bonded DMSO and of the
nitrogen ligand in A are gradually replaced by new signals, still attributable to bound
ligands.
Figure 5. Visible spectral changes observed in step 1 for Na[trans-RuC14(DMSO)(Im)] (2
x 10-4 M; 60 mM phosphate buffer pH 7.4; T 25 C; scan time interval 5 min).
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The case of the N-methylimidazole derivative is particularly significative to this regard
and is reported in Figure 6. Upon chloride dissociation, the broad resonance of DMAO
moves from -15 ppm to approx -11 ppm, while the sharper resonance of N-CH3 moves
from -1 ppm to + 1 ppm. Only one signal for the imidazole protons could be detected (it
moves from-3.8 pprn to-0.5 ppm during step 1), the others being very likely too broad
to be detected. Only a small amount of free DMSO (6%) could be found at the end of
step 1. The reaction rate of this step increases along with the pH.
Figure 6. Changes observed in the 1H NMR spectrum of Na[trans-
RuC14(DMrlg)(Melm)] during step 1. Only the most relevant part of the spectrum is
shown.
O0 rain
t;O
We also found that, in the presence of catalytic amounts of reducing agents, the reaction
rate remarkably increases and the kinetic profile becomes of pseudo-first order (Figure
7). These data suggest that chloride substitution is catalyzed by traces of Ru(II) species;
similar processes have already been described for inert Ru(lll) species [20]. In the
absence of added reductants, we hypothize that an autoreduction process, parallel to the
substitution reaction, is the source of Ru(ll) species. A partial reduction due to trace
impurities in solution would not explain the autocatalytic pattern, since in that case the
amount of catalyst would be constant since the beginning.
The presence of traces of added biological reductants promotes the formation of an
equivalent amount of catalyst, so that the reaction proceeds mainly through the catalyzed
path and becomes zero order in the catalyst and first order in the reactant.
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In the second step of the reaction the product that built up in step 1 is transformed into a
new species. This process involves the decrease of the absorption maximum at approx
346 nm, with formation of a new maximum at higher frequencies (325 nm) and a
concomitant gradual increase of the background absorption (Figure 8). An isosbestic
point is still maintained.
Figure 7. Visible spectral changes observed in step 1 for [NEt4][trans-
RuC14(DM,50)(Im)l in the presence of 1% glutathion (GSH) ([Rul 2 x 10-4 M; [GSH]
2 x 10-t) M; 60 mM phosphate buffer pH = 7.4; T 25 C; scan time interval 5
min).
Step 2 is independent on the concentration of OH- and, unlike step 1, its rate is not
influenced by the presence of trace reductants. However, stoichiometric amounts of
reductants introduced in solution at this stage determine complete reduction to Ru(ll)
species.
In agreement with the blue-shift observed in the visible spectrum, step 2 has been
tentatively attributed to the dissociation of a further chloride but, according to the NMR
spectra, it is also accompanied by the partial dissociation of DMSO and of the nitrogen
ligand. However, since no new signals for bound ligands appear in the NMR pattern
during this step, formation of a dimeric species might be also hypothized. In this
hypothesis the presence of two paramagnetic centers would broaden the signals of
coordinated ligands to such an extent as to make them undetectable.
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The following step 3 is accompanied by a general increase of the background
absorption, attributed to the formation of polymeric species. The chemical behavior at
physiological pH is summarized in Scheme 5, where the likely deprotonation equilibria of
the aquo species have been also evidenced.
Figure 8. Visible spectral changes observed in step 2 for Na[trans-RuC14(DMSO)(Im)l (2
x 10-4 M; 60 mM phosphate buffer pH = 7.4; T 25 C; scan time interval 10 rain).
,=-.
As a general conclusive remark, we can state that, owing to the reinforcement of the
Ru-S bond, all complexes of class A are indeed remarkably more inert than their
precursors in aqueous solution at physiological pH.
We also investigated the behavior of the complexes in the presence of a slight excess of
a nitrogen ligand, such as imidazole (lm/Ru 10), in order to mimic the presence of the
biological targets. Step 1 and 2 are unaffected by the nitrogen ligand, while in the last
step the backgroud absorption increase becomes almost negligible and a new species with
an absorption maximum around 290 nm forms.
This behavior suggests that i) the complexes are not reactive as such towards the
biological targets but must first undergo a series of chemical transformations; ii) in a
biological environment, due to the abundance of possible reactants, the formation of
polymeric species should be prevented. Moreover, due to the aboundance of reductants in
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biological systems, the complexes might become reduced before undergoing any
dissociation process. For the sake of comparison, we found that ICR is considerably
more inert compared to the sulfoxide derivatives of class A also at physiological pH and
it is not affected by reductants.
Scheme 5. Chemical behavior of the complexes of class A at physiological pH
CI
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Pharmacology. The investigations aimed to evaluate the antitumor activity of the above
compounds were carded out with tumors such as Lewis lung carcinoma, B16 melanoma,
TLX5 lyrnphoma, P388 lymphocytic leukemia and MCa mammary carcinoma. However,
a large part of the characterization of the effects of ruthenium(III)-dimethylsulfoxide
complexes on metastasizing tumors has been done on MCa mammary carcinoma. This
tumor, similarly to almost all solid mtastasizing tumors, after s.c. or i.m. implantation
produces distant metastases (to the lungs) and threfor appears to be suitable for
studying anticancer agents active on the disseminated tumor.
The results of the differential effects of a series of class A ruthenium complexes on
primary tumor growth and on the formation of spontaneous pulmonary metastases in the
model of MCa mammary carcinoma of CBA mouse are reported in Table 2.
Table 2. Differential effects of some complexes on primary tumor growth and on lung
metastasis formation.
[Compound lOose [Primary tumor [Lung metastases
Controls
Na[trans-RuC14(DMSO)Iml
Na[trans-RuC14(DMsO)Ind]
Na[trans-RuC14(TMSO)Iql
Na[trans-RuC14(DMSO)Oxl
mg/Kg/day
100
50
25
90
45
22.5
30
15
7.5
90
45
22.5
weight (g)
1948_+ 151
10604-194"
1644+ 138
1687+227
1606+/-221
2079+/-152
1738+/-172
2079+/-240
2348+/-122
1931+/-189
766+/- 77**
1282+/- 80**
2086+/-195
numbe,,r
31.0+_2.0
11.2
18.7+3.7"
35.0+13.1
6.0+2.0**
8.3+2.3**
13.2+2.5"
13.7+3.3"
11.2+2.2"
16.3+3.5"
weight (mg)
14.6+2.4
0.04
0.6+0.3**
7.3+5.2*
0.9+0.3**
2.0+0.8**
8.1_+2.2"
7.0_+2.2**
3.8_+0.7**
10.9+_2.2
1 0.13
3.6+0.4** 0.4+0.1"*
19.0+4.7" 6.0+2.6**
6/8 animals free of macroscopically detectable metastases; * and ** mean statistically different from
controls at p< 0.05 and p< 0.01 level, respectively (Student-Newman-Keuls analysis of variance).
Groups of 8 mice, implanted i.m. with 106 MCa mammary carcinoma cells on day 0, were given i.p. the
test compounds on days 1,5,9,13. Primary tumor weight was determined on day 14 and lung metasases were
counted on day 21.
From these studies it is evident how, independently on the compound being used, the
effects on lung metastasis formation are always higher than those on primary tumor
growth. Interestingly, Na[trans-RuC14(TMSO)Iq] that, given the significant cytotoxicity
for tumor cells evidenced in dtro against TLX5 lymphoma cells (Table 3), was expected
to give the higher reduction of primary tumor growth, resulted instead endowed with a
rather weak activity against tumor growth and lung metastases; similarly it resulted
scarcely active on TLX5 lymphoma or on P388 leukemia, including the cisplatin resistant
subline, after in dvo treatments (Table 4). Conversely, compounds such as Na[trans-
RuC14(DMSO)Im] or Na[trans-RuC14(DMSO)Ox], completely devoid of in 4tro
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cytotoxicity, significantly reduced primary tumor growth and gave an even more
pronounced reduction of the formation of spontaneous pulmonary metastases in the same
animals. These effects have been obtained at doses that are equitoxic for the host in that
cause the same effect on body weight gain during treatment.
Table 3. Effects of some complexes on TLX5 lymphoma in 4tro.
Compound Optimal ILS% DE50
Na[trans-RuC14(DMSO)Im]
Na[trans-RuC14(DMSO)Oxl
Na[trans-RuC14(DMSO)Ind]
Na[trans-RuC14(DMSO)lq]
Na[trans-RuC14(TMSO)Iq]
+7.4
+8.4
+24
+32
100% cured
> > 10-3M
> > l’0-3M
> 10-’3M
> 10’3M
10-4> 10-SM
Global
assesment
++
++++
Optimal ILS%: optimal increase of survival time over untreated controls; DE50: Molar concentration that
increses by 50% the life span of the transplanted mice; Global assesment: and + indicate the relative
potency of the compounds; inactive.
Groups of 5 CBA male mice, transplanted i.p. with aliquots of" 0.1 ml of an incubation mixture containing
106 TLX5 lymphoma cells per ml kept/n tro at 37C for 60 rain in the presence of 10-5, 10-4 or 10-3M
concentrations of each compound, were evaluated for tumor development and survival time. 100% cured
means that no transplanted animal developed tumor within 90 days.
Anyhow, it must be stressed that, although the activity on tumors of lymphoproliferative
type such as the P388 lymphocytic leukemia are not much impressive (Table 4), all
compounds tested were active on the cisplatin resistant line, in some cases with an
activity clearer than that observed on the parental line, thus indicating that ruthenium-
dimethylsulfoxide complexes do not exibit cross resistance with cisplatin itself.
Table 4. Effects of some complexes on TLX5 lymphoma and on P388 or P388/DDP
leukemias in 4vo.
Compound
Na[trans-RuC14(DMSO)Im]
Na[trans-RuC14(DMSO)Indl
Na[trans-RuC14(DMSO)Iql
TLX5 lymphoma
nt
120 [20]
122 I20l
P388
170 [401
156 [201
168 I401
P3’88)DP
162 I10l
152 [201
162 [201
Na[trans-RuC14(TMSO)Iq] 124 [10] 121 [101 139 I10,|
Each value is the mean %TIC obtained at the optimal dose [in brackets as mg/Kg/day] with groups of 5 mice
treated i.p. daily on days 1-7 from i.p. tumor implantation of 105 TLX5 lymphoma cells or of 106 cells of
P388 leukemia or of its eisplatin resistant line.
Out of the compounds studied so far, only Na[trans-RuC14(DMSO)Im] (5) exibited an
interesting relationship between inhibition of primary tumor growth and increase of
survival time of the treated hosts, with a global efficacy independent on the tumor line
being used. Complex 5 reduces the growth of solid tumors implanted i.m. or s.c. [see
also data from ref. 53,54] and parallely increases the survival time of the same animals
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also when the effects on primary tumor growth are not as pronounced as one would
expect to account for the increased life-span. In this context, it must be emphasized that
cisplatin, even when capable of reducing i.m. tumor growth of MCa mammary
carcinoma by more than 90% (as resulting from a separate experiment designed as to get
primary tumors at 2-weeks of less than 0.5 g) was practically inactive on host survival
time (T/C= 121+20%). The effects of 5 on survival time could be explained, if not
completely at least in part, by its potent effectiveness in reducing lung metastasis
formation, as results from studies on lung metastasis either spontaneously formed from
i.m. tumor implants or artificially obtained by i.v. implantation of tumor cells (Table 5).
The antimetastatie effects of 5 depend on the treatment schedule chosen and, similarly to
what observed on primary tumors, are more pronounced with low doses given daily
rather than with large doses given with drug-free intervals (see also data from ref. 54).
On the contrary, the activity on metastases of its analog Na[trans-RuC14(TMSO)Iq] is
less pronounced. These data further stress the absence of any correlation between in 4tro
cytotoxicity and in 4vo antitumor activity and seem to suggest that the increase of
lypophylicity of the complexes from logP= 3.79 of Na[trans-RuC14(DMSO)Im] to
logP= 1.91 of Na[trans-RuC14(TMSO)lq] (Table 1) does not produce benefits to the
antimetastatic properties.
Table 5. Effects of Na[trans-RuC14(DMSO)Im] and of Na[trans-RuC14(TMSO)Iq] on
spontaneous metastases and on lung colonies.
Compound Spontaneous metastases
Controls
Na[trans-RuCht(DMSO)Im
44 mg/Kg/day
Na[trans-RuC14(TMSO)Iq]
Number
17.4+5.5
3.5+1.0
11.7+3.2
Weight
8.1+3.6
0.8+0.5
4.1+0.8
Number
Lung colonies
Weight
21.4+2.8
12.7+_2.6
17.0+2.9
30.5+7.3
14.7+3.8
20 mg/Kg/day
Groups of 8 CBA female mice, implanted s.c. with 2X’10o MCa mammary carcinoma ceils (spontaneous
metastases) or i.v. with 105 MCa MCa mammary carcinoma cells (lung colonies) on day 0, were given i.p.
the test compounds on days 1-6 and were killed on day 21 or on day 18 for the evaluation of spontaneous
metastases or of lung colonies, respectively.
However, data from Table 5 further indicate that spontaneous metastases are a target
better than lung colonies artificially obtained by i.v. implantation of tumor cells. Thus,
Na[trans-RuC14(DMSO)Im] is not simply effective on tumors growing in the lungs
because of its possible higher concentration in the lung tissue, as suggested by a pilot
study performed by means of atomic absorption measurements [60], but probably also
because on spontaneous lung metastases it can overcome the problems of chemosensitivity
usually found within tumor cells of primary tumors, which can also be present on
artificial metastases. This behaviour can be explained taking into account the differences
in growth kinetics between spontaneous and artificially induced lung metastases, where
the latter have been described to show marked similarities with the primary tumor from
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which they arose [61,62]. Therefore, the selectivity of the effects of Na[trans-
RuC14(DMSO)Im] for lung tumors, unlike cisplatin that exerts its antitumor effects on
the primary tumor, seems to be attributable to the capacity of 5 to distinguish the
differences between tumor cell populations and to be more effective on those with higher
metastatic potential. Interestingly, at the lung level, Na[trans-RuC14(DMSO)lm] has no
evidence of toxicity for healthy lung epithelium, as results from histological analysis.
Despite the apparent lack of cytotoxic effects for tumor cells or for cells of healthy
tissues, Na[trans-RuC14(DMSO)lm] and the related complexes of class A are able to
interact with DNA in 4tro, binding to nucleobases and also causing interstrand cross-
links that in some cases are of the same magnitude as those caused by cisplatin under the
same conditions (Table 6).
The sequence specificity ofDNA modification by ruthenium complexes was investigated
by the primer extension footprinting technique. DNA from plasmid pBR322 was
modified with class A complexes, and with ICR and cisplatin for comparison, by in 4tro
treatment at 37C for lhr, according to standard methods. The DNA was primed with
Pst(+) primer and used as a template for second strand synthesis by Sequenase 2
enzyme. The ruthenium(lll)-sulfoxide complexes block replication, as evidenced by the
stop sites observed on sequencing gel; on the contrary ICR produces no stop sites. All
class A complexes investigated so far have the same pattern of blocking lesions, showing
faint stop bands corresponding to nearly every nucleotide, with the exception of thymine,
and more intense stop bands corresponding to guanines. This behaviour could reflect a
high capability of class A complexes (probably in an hydrolized form) to attack DNA
and, consequently, a great tendency of the polymerase to be dissociated from the treated
template.
Table 6. Effects of some ruthenium(III) complexes on the % of interstrand cross-linked
DNA.
Compound Drug/Nucleotide concentration ration (xl0-2i ’....
0.25 0.5 1 2
’Cisplatin 4.04+0.28 8.01+0.69 "15.4+1.12 ..29.0+0.14
ICR 0 0 0 0
Na[trans-RuC14(DMSO)Im1 0.34+0.08 0.82+0.35 2.20+0.41 7.38+0.45
Na[trans-RuC14(DMSO)lnd] 1.46+0.48 3.42_+0.55 7.23+ 1.35 14.9+0.28
Na[trans-RuCl4(TMSO)Iql 1.57+0.26 3.39+1.18 10.7+0.41 ’23.9+1.11
NaItrans-RuC14(DMSO)Oxl 3.33+0.31 6.04+2.85 12.7+0.77 24.8+ 1.12
In vitro incubations were made at 370C for 60 mm, and the % of interstand cross-links was determined by
meand of the ethidium bromide fluorescence assay, by a modification of the method of Morgan and
Pulleybank [63| and Brent [64].
Unlike the above ruthenium(III)-sulfoxide complexes, some ruthenium(ll)-sulfoxides
derivatives such as trans-RuC12(DMSO)4 show a remarkable specificity in DNA
interaction, similar to that of cisplatin, being capable of interacting almost exclusively
with guanine sequences with G> 2 [48 ].
From the compared examination of data of Table 6 and of the effects on experimental
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tumors it appears that the amount of interstrand cross-linking to DNA and antitumor
action are completely separated. In fact, two compounds such as Na[trans-
RuC14(DMSO)Im] and Na[trans-RuC14(DMSO)Ox], that exibit a similar pattern of
activity on MCa mammary carcinoma in 4vo (Table 4) and a similar lack of activity
against TLX5 lymphorna in 4tro (Table 3), behave quite differently towards DNA
interstrand cross-linking, the former being scarcely effective whereas Na[trans-
RuC14(DMSO)Ox] is highly effective, with percentages of interstrand cross-linking
similar to those of cisplatin at any D/N ratio tested.
If from one hand the ,,toxicity,, for the metastatic cells seems to fulfill the proposed
theory of a more likely activation of ruthenium(IIl) complexes to cytotoxic products into
tumor cells rather th.an in cells of healthy tissues [20-25], from another point of view it is
difficult to explain the significantly lower activity against tumor cells of primary tumors
or of lung colonies artificially induced by i.v. injection of tumor cells. A contribution to
the antimetastatie action due to an effect at primary site of growth is however observed
with Na[trans-RuC14(DMSO)Im], as shown by the reduced metastatic ability of MCa
mammary carcinoma in mice transplanted with tumor cells treated in dvo with
antimetastatie effective doses of 5. Indeed, such property is evident only at the highest
dose used, indicating that this effect can be only in part responsible of the overall activity
of Na[trans-RuC14(DMSO)lm] on lung metastasis formation of MCa mammary
carcinoma. In fact, the effects at primary site of tumor growth show an unexpected
complexity. The reduction of primary tumor growth is only minor and the effects have no
long lasting consequence since tumor cells maintain their clonogenic capacity when
transplanted into intact syngenic hosts (Sava et al., data on file). Similarly, no evidence
of residual effect at this site, as far as metastasizing capacity is concerned, is seen since,
after discontinuation of treatments, residual tumors grow and metastasize as no previous
treatment had occurred.
Finally, the possibility that the antimetastatic effects of Na[trans-RuC14(DMSO)lrn]
could be fully ascribed to the differentiating action of dimethylsulphoxide should also be
ruled out. In fact ICR [27,281, in which the dimethylsulfoxide ligand has been replaced
by an imidazole moiety, is as effective as 5 on lung metastases of MCa mammary
carcinoma (unpublished results). Indeed, the presence of even small amounts of free
DMSO in the solution used for treatments reduces the antitumor activity of Na[trans-
RuC14(DMSO)Im]; an action similar to that shown for the structurally related complex
[mer-RuC13(DMSO)2NH3] [521.
The favourable selective antimetastatie properties described in the previous paragraphs
for the ruthenium(IlI)-dimethylsulfoxide complexes of class A in general, and for
Na[trans-RuCl4(DMSO)Im] in particular, are further stressed by the results obtained
testing the therapeutic potential of this compound when combined with surgical excision
of primary tumor (Table 7). The high propensity to reduce the growth of lung metastases
is evidenced also when treatment occurs after surgical ablation of primary tumor, that is
on an advanced stage of growth of the metastatic tumor. In this condition, a treatment
schedule can be found that significantly prolongs the life-span of the tumor-bearing
animals with an efficacy that is in agreement with the effects of reduction of lung
involvement by the metastatic tumor (Table 8).
Again, as shown previously, Na[trans-RuC14(TMSO)Iq] is scarcely active after in t4vo
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treatment also on host’s survival time (Table 7).
Table 7. Effects of Na[trans-RuC14(DMSO)lm] and of Na[trans-RuC14(TMSO)lq] on the
survival time of mice beating MCa mammary carcinoma and undergoing surgical
excision of primary tumor.
Compound
mean __. S.E.
Controls 26.0+4.2
Na[trans-RuC14(DMSO)Im] 44.9_+4.6
Na[trans-RuC14(TMSO)Iq] 22.9+2.9
Groups of 10 mice, implanted i.m. with 106 cells of MCa
Survival time
median
21
52
(d,ay s)
Survivors day 21
50%
100%
63%
mammary carcinoma and undergoing surgical
amputation of primary tumor on day 14, were given i.v. 60 mg/Kg/day Na[trnns-RuC14(DMSO)Im] or 35
mg/Kg/day Na[trans-RuCl4(TMSO)Iq] on days 1,5,9,13.
On the other hand, data on the effects of Na[trans-RuCl4(DMSO)Im| on host’s survival
time are of noteworthy importance in that show the complex capable of a therapeutic
activity. They indicate that, unlike many other compounds resulted capable of preventing
metastasis formation so far, including Razoxane, DTIC and related triazenes that were
active if given before implantation of metastases in the lungs, 5 is effective also when the
treatment simulates a rather common clinical situation where drug treatment is applied
always after metastatization had already occurred (Table 8). Na[trans-RuC14(DMSO)Im]
reduced the growth of established lung metastases and significantly prolonged the life-
span of the tumor-bearing animals.
Table 8. Effects of Na[trans-RuC14(DMSO)Im] on lung metastasis formation and on the
postsurgical survival time in mice beating MCa mammary carcinoma and undergoing
surgical amputation of primary tumor.
Treatment group Lung metastasis weight Survival time (days)
(mg) % ILS
none
44 mg/Kg/day on days 1-6.
44 mg/Kg/day lhr before .surgery
22 mg/Kg/day on days 1-12
107.9+ 19.4
41.1+11.0" 15.7
%ILS: percent increase vs controls;
A: given in two separate injections, with 1 hr interval, of 22 mg/Kg/day each;
*: p< 0.05 and **: p<0.01 vs controls.
Groups of CBA mice, inoculated i.m. with 106 MCa mammary carcinoma cells on day 0 and tmdergomg
surgical amputation of primary tumor on day 12, were given Na[trnns-RuCl4(DMSO)Im] as mdicatexl,
starting 24 hr after surgical intervention.
Conclusions.
The examination of the antitumor potential of ruthenium(III) complexes with
dimethylsulfoxide ligands has pointed out their differential effects depending on the
tumor and on the site of tumor growth, i.e. primary or metastatic site.
The effects on the survival time correlate with those on lung metastases and indicate the
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importance of the optimization of parameters such as treatment schedule and daily
dosage. Anyhow, the evidence of activity on advanced lung metastases is extremely
important in that the model is strictly closed to the most common human situation in
which often cancer patients, after successful radical surgery and/or radiotherapy, show
the appearance of disseminated metastases that are refractory to conventional cytotoxic
treatments because of their nature different from that of the primary tumors from which
arose and because the conventional agents actually available have been developed by
studies of activity against primary tumors rather than on their metastases. Therefore
ruthenium(lll)-sulfoxide complexes of class A, and Na[trans-RuC14(DMSO)lm] in
particular, appear to be a new class of compounds that exibit a selective activity against
spontaneous metastases that could be of benefit in the therapy of human neoplasm.
As could be easily expected, class A complexes are not able to interact with biological
targets as such, but must undergo an activation process, either by reduction or by
hydrolisis. All derivatives behave similarly in physiological solution, even though minor
differences concerning the rate of hydrolisis of both anionic and neutral ligands have been
evidenced, depending on the nature of the nitrogen ligand. Also the redox potential is
almost unaffected by the nature of the nitrogen ligand. Parameters such as lipophylicity
and steric hindrance of the nitrogen ligand are more likely to be factors of discrimination
in the biological behavior of the single derivative, that has been observed both at the
level of in vitro DNA interactions and of in vivo antitumor properties.
It should be also stressed that, despite the apparent similarity between compounds of
class A and derivatives like ICR, the substitution of a nitrogen ligand with a sulfoxide
involves rather dramatic changes in foundamental chemical properties of the complex,
such as redox potential and rate of hydrolisis of the ligands. Even though, rather
surprisingly, the antitumor acivity of the two types of compounds is quite similar in the
models examined by us so far, the differences in chemical properties are reflected both in
their different capability of interaction with DNA and in the different toxicity and
tolerability.
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